查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995463

类固醇注射市场：按分子类型、治疗类型、患者类型、适应症、最终用户和分销管道划分－2026-2032年全球市场预测

Steroid Injections Market by Molecule Type, Treatment Type, Patient Type, Therapeutic Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，类固醇注射剂市场价值将达到 57.2 亿美元，到 2026 年将成长至 62 亿美元，到 2032 年将达到 103.9 亿美元，复合年增长率为 8.90%。

主要市场统计数据
基准年 2025 57.2亿美元
预计年份：2026年 62亿美元
预测年份：2032年 103.9亿美元
复合年增长率 (%) 8.90%

对塑造现代类固醇注射实践和广泛应用的临床、营运和监管环境进行了权威概述。

皮质类固醇注射在介入治疗和保守治疗之间发挥桥樑作用，在现代疼痛管理和肌肉骨骼疾病治疗中占据核心地位。皮质类固醇注射仍是临床医生治疗发炎性疾病、急性发作以及关节、软组织和脊椎腔内特定部位疼痛的主要治疗方法。近年来，随着疗效比较数据的累积、对标靶给药的日益重视以及影像引导技术的应用，临床实践不断发展，以提高注射的准确性和安全性。

精准给药、供应链韧性和支付方主导的证据要求方面的进步，如何从整体上重塑类固醇注射的实践和商业化？

目前，类固醇注射疗法正经历着一场变革性的转变，这主要得益于临床技术的进步、供应链的重组以及支付者期望的改变。在临床方面，包括超音波和透视引导在内的精准注射方法正在加速普及，从而提高了标靶准确性并减少了手术相关併发症。同时，疼痛专科医生、骨科医生和介入放射科医生之间的培训项目不断加强，跨学科合作也日益普及。此外，以患者为中心的治疗路径也越来越受到重视，这些路径将注射治疗与康復、药物治疗优化以及患者参与决策相结合。

近期关税变化对营运和商业产生了哪些影响？采购、製造和分销领域的相关人员如何调整以维持供应的连续性？

2025年实施的关税措施进一步增加了参与类固醇注射疗法相关医疗产品生产、分销和采购的相关人员的复杂性。进口关税和双边贸易措施的变化可能会影响活性成分、辅料和手术医疗设备的成本基础，促使製造商重新评估与供应商的合约并探索近岸外包的机会。因此，采购团队和对采购敏感的设施越来越关注总到岸成本、前置作业时间波动和供应商多元化，以降低与贸易相关的价格波动风险。

根据细分市场分析制定目标策略，该分析能够解读分子选择标准、治疗背景、患者人口统计特征、治疗适应症、医疗环境和分销管道。

精准的市场区隔对于协调类固醇注射的临床开发、商业策略和分销计划至关重要。从分子类型来看，此细分市场包括地塞米松、Hydrocortisone、Methylprednisolone和曲安奈德等药物，每种药物都具有其独特的效力、作用持续时间和安全性，这些因素会影响临床选择和製剂定位。治疗类型细分则明确了关节注射、软组织注射和脊椎注射等手术的具体情况。关节注射进一步分为大关节和小关节；软组织注射再细分为滑囊注射、韧带注射和肌腱注射；脊椎注射则分为硬脊膜外注射和鞘内注射。这些区分反映了特定操作的训练要求、医疗设备需求以及报销代码的细微差别。

影响临床实践模式、监管方法和供应链策略的美洲、欧洲、中东和非洲以及亚太地区的区域趋势。

区域趋势对类固醇注射的临床实践模式、监管预期和商业性策略有显着影响。在美洲，成熟的门诊基础设施、微创疼痛管理计画的高普及率以及支付方对治疗效果和合理使用的严格审查，共同塑造了该疗法的应用。美洲内部的跨境贸易和采购关係也影响筹资策略，并可能创造建立区域製造地的机会，从而缩短前置作业时间并降低关税风险。

深入了解製药公司、医疗设备创新者和服务供应商如何整合证据、供应链弹性和综合解决方案，以有效参与竞争。

类固醇注射产品和服务的竞争格局由成熟的製药公司、支援手术操作的医疗设备供应商以及在临床环境中提供解决方案和培训的专业服务机构组成。领先的製药企业优先考虑透过改进配方、确保稳定供应和验证临床安全性来实现产品组合的差异化。同时，医疗设备製造商也在推动药物输送系统和影像引导相容性方面的创新，以提高手术的精准度和工作流程的效率，从而为满足製药和医疗设备双方需求的捆绑式解决方案创造了机会。

製造商和供应商可采取的策略重点是加强证据产生、实现供应链多元化以及建构综合治疗和给药解决方案。

为了在类固醇注射剂领域保持长期竞争力，产业领导企业必须采取积极主动的策略，协调临床证据的产生、供应链策略和商业性执行。首先，各企业应优先投资于真实世界资料（RWE）计画和上市后监测，以揭示不同适应症和给药途径下相对安全有效的疗效。这些证据将有助于製定药物采纳清单、与支付方进行谈判以及推动临床医生采纳，同时也指南产品的持续改进。

为了得出确切的结论，我们采用了一种透明的混合方法研究途径，结合了对临床医生的访谈、采购方面的见解、监管审查和文献整合。

本分析的调查方法融合了定性和定量方法，旨在全面了解临床实践、供应动态和商业性驱动因素。主要研究包括对常规注射类固醇的专科临床医生、医院和门诊中心的采购经理以及生产和分销公司的管理人员进行结构化访谈。这些访谈提供了关于手术量、临床医生对药物分子和给药方法的偏好以及与库存和采购相关的营运挑战的第一手资讯。

一项权威性的综合分析强调了临床价值、供应韧性和跨部门策略是未来提供类固醇注射护理成功的决定因素。

总之，类固醇注射仍然是肌肉骨骼和疼痛管理实践中不可或缺的一部分，这得益于技术创新、精准的临床应用以及高度灵活的给药模式。相关人员面临着日益重视精准给药、支付方对主导医学的期望以及潜在的供应链压力（包括贸易相关的成本波动）等诸多挑战。因此，强调可靠的真实世界证据、多元化的采购管道以及整合的产品和服务交付的策略应对措施，被认为是满足临床医生和医疗机构需求并保持营运韧性的关键。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：类固醇注射市场：依分子类型划分

  • 地塞米松
  • Hydrocortisone
  • Methylprednisolone
  • 曲安奈德

第九章：类固醇注射市场：依治疗类型划分

  • 关节注射
    • 大关节
    • 小关节
  • 注射到软组织
    • 滑囊注射
    • 韧带注射
    • 肌腱内注射
  • 脊椎注射
    • 硬脊膜外麻醉
    • 鞘内腔

第十章：类固醇注射市场：依病患类型划分

  • 成人
  • 老年人
  • 儿童

第十一章：类固醇注射市场：依适应症划分

  • 腰痛
    • 腰痛
    • 坐骨神经痛
    • 上背部疼痛
  • 黏液囊炎
  • 骨关节炎
  • 类风湿性关节炎
  • 肌腱炎

第十二章：类固醇注射市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 医院
    • 综合医院
    • 专科医院

第十三章：类固醇注射市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十四章：类固醇注射市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：类固醇注射市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：类固醇注射市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国注射类固醇市场

第十八章：中国註射类固醇市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4103B31E091F

The Steroid Injections Market was valued at USD 5.72 billion in 2025 and is projected to grow to USD 6.20 billion in 2026, with a CAGR of 8.90%, reaching USD 10.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.72 billion
Estimated Year [2026] USD 6.20 billion
Forecast Year [2032] USD 10.39 billion
CAGR (%) 8.90%

An authoritative introduction to the clinical, operational, and regulatory landscape shaping contemporary steroid injection practice and procedural adoption

Steroid injections occupy a central role in contemporary pain management and musculoskeletal care, bridging interventional treatment and conservative therapies. Corticosteroid injections remain a mainstay for clinicians managing inflammatory conditions, acute exacerbations, and targeted pain relief across joints, soft tissues, and spinal spaces. Over recent years, clinical practice has evolved in response to accumulating comparative effectiveness data, a greater emphasis on targeted delivery, and the integration of image-guided techniques that enhance precision and safety.

Clinicians and hospital systems have adapted procedural pathways to balance efficacy, patient safety, and operational throughput. Concurrently, regulatory scrutiny and payer engagement have influenced procedural adoption by foregrounding outcomes, safety profiles, and appropriate use criteria. The combination of technological refinements, heightened demand for minimally invasive interventions, and an aging population with chronic musculoskeletal conditions has kept steroid injections in active clinical use while stimulating continued innovation in formulations, delivery systems, and procedural protocols. This introduction frames the subsequent analysis by situating steroid injections within a dynamic clinical, commercial, and regulatory ecosystem.

How advances in precision delivery, supply chain resilience, and payer-driven evidence requirements are collectively reshaping steroid injection practice and commercialization

The landscape for steroid injections is undergoing transformative shifts driven by converging clinical advances, supply chain realignments, and shifting payer expectations. Clinically, there is an accelerating adoption of precision approaches, including ultrasound and fluoroscopy guidance, which improve targeting and reduce procedure-related complications; this trend is complemented by enhanced training programs and cross-disciplinary collaboration between pain specialists, orthopedists, and interventional radiologists. Moreover, there is heightened attention to patient-centered care pathways that integrate injection therapy with rehabilitation, pharmacologic optimization, and shared decision-making.

On the supply chain front, manufacturers and distributors have responded to raw material constraints, logistics challenges, and regulatory changes by diversifying sourcing strategies and investing in regional manufacturing resilience. In parallel, health systems have intensified evaluations of procedural value, requesting stronger evidence for comparative effectiveness and longer-term outcome measures, thereby prompting manufacturers to focus on real-world evidence generation and payer engagement. Technological innovation extends beyond imaging to include targeted-release formulations and delivery adjuncts that seek to extend symptom relief while minimizing systemic exposure. Taken together, these shifts are reshaping how steroid injections are developed, delivered, and reimbursed, creating new imperatives for stakeholders to adapt commercial models and clinical protocols.

Operational and commercial repercussions of recent tariff changes and how procurement, manufacturing, and distribution stakeholders are adapting to maintain supply continuity

Tariff policies enacted in 2025 have introduced an additional layer of complexity for stakeholders involved in the manufacture, distribution, and procurement of medical products related to steroid injection therapy. Changes in import duties and bilateral trade measures have the potential to affect the cost base for active pharmaceutical ingredients, excipients, and medical devices used in procedural delivery, prompting manufacturers to reassess supplier contracts and to explore nearshoring opportunities. As a result, procurement teams and procurement-sensitive facilities have heightened their focus on total landed cost, lead-time variability, and supplier diversification to mitigate exposure to trade-related price shocks.

In response to tariff-induced pressures, several strategic responses have emerged across the value chain. Manufacturers have accelerated assessments of alternative sourcing jurisdictions and have revisited inventory policies to balance working capital considerations against the risk of supply disruptions. Distributors and hospital systems have adjusted contracting frameworks to incorporate tariff pass-through clauses and more flexible procurement terms. At the same time, regulatory authorities and industry associations have engaged in dialogue to clarify classification and duty treatments for complex pharmaceutical products and combination devices. While tariffs have not changed clinical indications or practitioner decision-making directly, they have catalyzed operational and commercial adaptations that influence pricing strategies, supply continuity planning, and the pace of product innovation.

Segment-by-segment analysis that decodes molecule preferences, procedural contexts, patient demographics, therapeutic indications, care settings, and distribution pathways for targeted strategy

A nuanced understanding of market segmentation is essential to align clinical development, commercial strategy, and distribution planning for steroid injections. When considering molecule types, the field encompasses agents such as dexamethasone, hydrocortisone, methylprednisolone, and triamcinolone, each with distinct potency profiles, duration of action, and safety considerations that influence clinical selection and formulary positioning. Treatment type segmentation delineates procedural contexts including joint injections, soft tissue injections, and spinal injections, with joint injections further differentiated by large joints and small joints, soft tissue injections subdivided into bursa injections, ligament injections, and tendon injections, and spinal injections differentiated into epidural and intrathecal procedures; these differentiations reflect procedure-specific training requirements, device needs, and reimbursement coding nuances.

Patient type segmentation-adult, geriatric, and pediatric-imposes important variations in dosing strategies, safety monitoring, and clinical outcomes, with geriatric patients often presenting comorbidities that influence therapeutic choice and follow-up protocols. Therapeutic indication segmentation covers conditions such as back pain, bursitis, osteoarthritis, rheumatoid arthritis, and tendonitis, and back pain is further analyzed across lower back pain, sciatica, and upper back pain; these indication-level distinctions inform trial design, outcome metrics, and the expected duration of symptom relief sought by clinicians and patients. End-user segmentation identifies ambulatory surgical centers, clinics, and hospitals as the primary delivery settings, with hospitals further categorized into general hospitals and specialty hospitals, reflecting differences in procedural volume, inpatient integration, and credentialing requirements. Distribution channel segmentation highlights hospital pharmacies, online pharmacies, and retail pharmacies, and retail pharmacies are further divided into chain pharmacies and independent pharmacies, indicating distinct procurement behaviors, inventory management capabilities, and contractual dynamics. Synthesizing these segmentation layers reveals differentiated commercialization pathways, targeted evidence requirements, and bespoke distribution strategies that manufacturers and service providers must design to meet the clinical and operational realities of each segment.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence clinical practice patterns, regulatory approaches, and supply chain strategies

Regional dynamics exert a strong influence on clinical practice patterns, regulatory expectations, and commercial approaches for steroid injections. In the Americas, procedural utilization is shaped by a mature outpatient infrastructure, a high prevalence of minimally invasive pain management programs, and payer scrutiny that emphasizes outcomes and appropriate use. Cross-border trade and procurement relationships within the Americas also influence sourcing strategies and can create opportunities for regional manufacturing hubs that reduce lead times and tariff exposure.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory frameworks, reimbursement systems, and clinical practice traditions vary significantly across countries. This diversity encourages differentiated market access approaches, with some jurisdictions prioritizing stringent evidence packages while others adopt pragmatic reimbursement models that favor procedural adoption in ambulatory and specialized settings. Meanwhile, the Asia-Pacific region is characterized by rapid expansion of outpatient procedural capacity, growing investment in clinical training and imaging infrastructure, and a dynamic mix of local manufacturers and multinational entrants. Across regions, stakeholders must navigate local regulatory nuances, clinical practice patterns, and supply chain configurations to effectively deploy products and services, and regional partnerships or manufacturing investments can materially influence speed to market and operational resilience.

Insights into how pharmaceutical manufacturers, device innovators, and service providers are aligning evidence, supply resilience, and integrated offerings to compete effectively

The competitive landscape for steroid injection products and services is defined by a mix of established pharmaceutical manufacturers, device providers that support procedural delivery, and specialty service organizations that offer site-of-care and training solutions. Leading manufacturers prioritize portfolio differentiation through formulation improvements, quality of supply, and demonstrated clinical safety. At the same time, device makers are innovating around delivery systems and image-guidance compatibility to improve procedural precision and workflow efficiency, creating opportunities for bundled offerings that address both drug and device needs.

Strategic imperatives among companies include strengthening supply chain resilience, investing in real-world evidence generation, and cultivating deeper relationships with key end users such as ambulatory surgical centers and specialty hospitals. Partnerships between pharmaceutical firms and device providers, as well as collaborations with health systems and payer groups, have emerged as practical routes to accelerate adoption and to align commercial models with a value-based focus. Competitive differentiation increasingly hinges on the ability to demonstrate meaningful clinical outcomes, to support training and credentialing for proceduralists, and to offer flexible distribution models that account for hospital pharmacies, retail pharmacies, and the growing role of digital procurement channels. Companies that integrate clinical evidence, operational support, and supply reliability are better positioned to meet stakeholder expectations and to drive adoption across care settings.

Actionable strategic priorities for manufacturers and providers to strengthen evidence generation, diversify supply chains, and create integrated therapeutic and delivery solutions

Industry leaders must adopt a proactive posture that aligns clinical evidence generation, supply chain strategy, and commercial execution to sustain long-term competitiveness in the steroid injection space. First, organizations should prioritize investment in real-world evidence programs and post-market studies that articulate comparative safety and functional outcomes across indications and delivery techniques. Such evidence supports formulary discussions, payer negotiations, and clinician adoption while also informing continuous product improvement.

Second, commercial and procurement teams should collaborate to implement diversified sourcing strategies and to evaluate regional manufacturing options that reduce exposure to trade-related disruptions and tariff volatility. Strengthening relationships with hospital pharmacies, ambulatory surgical centers, and clinic networks through tailored logistics solutions and flexible contracting will enhance supply continuity. Third, companies should develop integrated offerings that pair therapeutics with compatible delivery devices and training services, thereby reducing barriers to adoption and improving procedural outcomes. Finally, leaders should engage early with payers and regulatory bodies to align evidence generation with reimbursement requirements and to anticipate changes in coding or appropriate use criteria. By translating these recommendations into concrete programs and cross-functional plans, organizations can accelerate adoption, enhance patient outcomes, and fortify commercial resilience.

A transparent mixed-methods research approach combining clinician interviews, procurement insights, regulatory reviews, and literature synthesis to ensure robust conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative techniques to build a comprehensive understanding of clinical practice, supply dynamics, and commercial drivers. Primary research included structured interviews with clinicians across specialties that routinely perform steroid injections, procurement leaders from hospitals and outpatient centers, and senior executives at manufacturing and distribution companies. These engagements provided first-hand insights into procedure volumes, clinical preferences for molecules and delivery methods, and operational challenges related to inventory and sourcing.

Secondary research encompassed regulatory filings, clinical guidelines, peer-reviewed literature on corticosteroid safety and efficacy, and public policy documents that affect trade and reimbursement. The analysis also incorporated trend synthesis from device registries and training program adoption metrics to understand the diffusion of image-guided procedures. Data triangulation across sources ensured that conclusions reflect consistent patterns rather than isolated observations. Where applicable, the methodology emphasized transparency in data provenance, a clear articulation of analytical assumptions, and sensitivity analyses to account for variability in practice patterns and supply chain configurations.

A conclusive synthesis emphasizing clinical value, supply resilience, and cross-functional strategies as determinants of future success in steroid injection care delivery

In conclusion, steroid injections remain a vital component of musculoskeletal and pain management practice, sustained by procedural innovation, targeted clinical application, and adaptable delivery models. Stakeholders face a landscape shaped by increasing emphasis on precision delivery, payer-driven evidence expectations, and supply chain pressures that may include trade-related cost variability. Strategic responses that emphasize robust real-world evidence, diversified sourcing, and integrated product-service offerings will be central to meeting clinician and institutional needs while preserving operational resilience.

Moving forward, the ability to translate clinical efficacy into demonstrable outcomes, to secure reliable and cost-effective supply channels, and to align commercial models with evolving reimbursement and regulatory requirements will determine competitive positioning. Cross-functional collaboration across clinical development, supply chain, and commercial teams is essential to convert insights into scalable programs that improve patient care and sustain organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Steroid Injections Market, by Molecule Type

  • 8.1. Dexamethasone
  • 8.2. Hydrocortisone
  • 8.3. Methylprednisolone
  • 8.4. Triamcinolone

9. Steroid Injections Market, by Treatment Type

  • 9.1. Joint Injections
    • 9.1.1. Large Joints
    • 9.1.2. Small Joints
  • 9.2. Soft Tissue Injections
    • 9.2.1. Bursa Injections
    • 9.2.2. Ligament Injections
    • 9.2.3. Tendon Injections
  • 9.3. Spinal Injections
    • 9.3.1. Epidural
    • 9.3.2. Intrathecal

10. Steroid Injections Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Steroid Injections Market, by Therapeutic Indication

  • 11.1. Back Pain
    • 11.1.1. Lower Back Pain
    • 11.1.2. Sciatica
    • 11.1.3. Upper Back Pain
  • 11.2. Bursitis
  • 11.3. Osteoarthritis
  • 11.4. Rheumatoid Arthritis
  • 11.5. Tendonitis

12. Steroid Injections Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals
    • 12.3.1. General Hospitals
    • 12.3.2. Specialty Hospitals

13. Steroid Injections Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies
    • 13.3.1. Chain Pharmacies
    • 13.3.2. Independent Pharmacies

14. Steroid Injections Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Steroid Injections Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Steroid Injections Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Steroid Injections Market

18. China Steroid Injections Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Bayer AG
  • 19.7. Bristol-Myers Squibb Company
  • 19.8. Johnson & Johnson
  • 19.9. Merck & Co., Inc.
  • 19.10. Novartis AG
  • 19.11. Pfizer Inc.
  • 19.12. Roche Holding AG
  • 19.13. Teva Pharmaceutical Industries Ltd.
  • 19.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STEROID INJECTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STEROID INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STEROID INJECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STEROID INJECTIONS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LARGE JOINTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SMALL JOINTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSA INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LIGAMENT INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDON INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STEROID INJECTIONS MARKET SIZE, BY EPIDURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STEROID INJECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STEROID INJECTIONS MARKET SIZE, BY LOWER BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SCIATICA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STEROID INJECTIONS MARKET SIZE, BY UPPER BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL STEROID INJECTIONS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STEROID INJECTIONS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL STEROID INJECTIONS MARKET SIZE, BY TENDONITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STEROID INJECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL STEROID INJECTIONS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL STEROID INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL STEROID INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL STEROID INJECTIONS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL STEROID INJECTIONS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL STEROID INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL STEROID INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 238. GCC STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. GCC STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 247. GCC STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GCC STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 277. G7 STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 286. G7 STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. G7 STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. NATO STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. NATO STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 294. NATO STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. NATO STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. NATO STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 299. NATO STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. NATO STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. NATO STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL STEROID INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA STEROID INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA STEROID INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA STEROID INJECTIONS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA STEROID INJECTIONS MARKET SIZE, BY JOINT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA STEROID INJECTIONS MARKET SIZE, BY SOFT TISSUE INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA STEROID INJECTIONS MARKET SIZE, BY SPINAL INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA STEROID INJECTIONS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA STEROID INJECTIONS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA STEROID INJECTIONS MARKET SIZE, BY BACK PAIN, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA STEROID INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA STEROID INJECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA STEROID INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA STEROID INJECTIONS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)